文献速递肿瘤 PET/CT骨显像与常规 SPECT核素与放射性配体治疗

探索用于评估前列腺癌骨肿瘤负荷的新型多模态定量成像指标:基于68Ga-PSMA PET/CT

Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using 68Ga-PSMA PET/CT.
PubMed 文献 · J Nucl Med · 2017-05-25

该研究提出2种结合CT解剖信息与68Ga-PSMA PET功能信息的多模态骨PET指数(BPIVOL与BPISUV),回顾性分析45例接受223Ra-二氯化物的去势抵抗性前列腺癌骨转移患者,评估其计算稳定性、可重复性及与前列腺特异性抗原、骨扫描指数和PERCIST分类的关系。结果显示两种指数观察者间最大差异为3.5%,与骨扫描指数显著相关(r分别为0.76和0.74,P<0.001),与前列腺特异性抗原值显著相关(r分别为0.57和0.54,P<0.01),且与专家PERCIST评级的一致性优于骨扫描指数。作者建议在前瞻性研究中评估BPIVOL和BPISUV作为68Ga-PSMA PET/CT成像生物标志物对骨转移患者结局预测的潜力。

要点

  • BPIVOL为受肿瘤影响的骨体积百分比,BPISUV额外考虑PSMA表达水平。
  • BPIVOL与BPISUV的观察者间最大差异为3.5%,计算仅需数分钟。
  • BPIVOL与BPISUV与骨扫描指数显著相关(r=0.76和0.74,P<0.001),与前列腺特异性抗原值显著相关(r=0.57和0.54,P<0.01)。

核心结论

  • 作者提出将BPIVOL和BPISUV作为68Ga-PSMA PET/CT的成像生物标志物,建议在前瞻性研究中评估其对前列腺癌骨转移患者结局预测的潜力。

研究设计与样本

  • 回顾性分析45例接受223Ra-二氯化物治疗的去势抵抗性前列腺癌骨转移患者的数据,定义2种骨PET指数(BPIVOL和BPISUV),并描述基于CT骨分割和PET病灶分割的半自动计算方法。

主要发现

  • 技术方面,BPIVOL和BPISUV的观察者间最大差异为3.5%,计算仅需数分钟。
  • 临床方面,BPIVOL和BPISUV与骨扫描指数显著相关(r=0.76和0.74,P<0.001),与前列腺特异性抗原值显著相关(r=0.57和0.54,P<0.01)。
  • 与专家PERCIST评级比较,BPIVOL和BPISUV的一致性优于骨扫描指数,提示其用于客观疗效评估的潜力。

关键数值与推荐

  • BPIVOL定义为受肿瘤影响的骨体积百分比,BPISUV额外考虑PSMA表达水平。
  • BPIVOL和BPISUV的观察者间最大差异为3.5%。
  • BPIVOL与骨扫描指数的相关系数r=0.76(P<0.001),BPISUV与骨扫描指数的相关系数r=0.74(P<0.001)。
  • BPIVOL与前列腺特异性抗原值的相关系数r=0.57(P<0.01),BPISUV与前列腺特异性抗原值的相关系数r=0.54(P<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET combined with CT and prostate-specific membrane antigen (PSMA) ligands has gained significant interest for staging prostate cancer (PC). In this study, we propose 2 multimodal quantitative indices as imaging biomarkers for the assessment of osseous tumor burden using 68Ga-PSMA PET/CT and present preliminary clinical data. Methods: We defined 2 bone PET indices (BPIs) that incorporate anatomic information from CT and functional information from 68Ga-PSMA PET: BPIVOL is the percentage of bone volume affected by tumor and BPISUV additionally considers the level of PSMA expression. We describe a semiautomatic computation method based on segmentation of bones in CT and of lesions in PET. Data from 45 patients with castration-resistant PC and bone metastases during 223Ra-dichloride were retrospectively analyzed. We evaluated the computational stability and reproducibility of the proposed indices and explored their relation to the prostate-specific antigen blood value, the bone scan index (BSI), and disease classification using PERCIST. Results: On the technical side, BPIVOL and BPISUV showed an interobserver maximum difference of 3.5%, and their computation took only a few minutes. On the clinical side, BPIVOL and BPISUV showed significant correlations with BSI (r = 0.76 and 0.74, respectively, P < 0.001) and prostate-specific antigen values (r = 0.57 and 0.54, respectively, P < 0.01). When the proposed indices were compared against expert rating using PERCIST, BPIVOL and BPISUV showed better agreement than BSI, indicating their potential for objective response evaluation. Conclusion: We propose the evaluation of BPIVOL and BPISUV as imaging biomarkers for 68Ga-PSMA PET/CT in a prospective study exploring their potential for outcome prediction in patients with bone metastases from PC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bieth M, Krönke M, Tauber R, et al. Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using 68Ga-PSMA PET/CT. J Nucl Med. 2017. PMID: 28546330. doi:10.2967/jnumed.116.189050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。